Moderna Inc. has recently reported encouraging interim findings from its Phase 1/2 trial involving a combination vaccine targeting both COVID-19 and the flu. In addition, the company has revealed plans to initiate a Phase 3 trial specifically for individuals aged 50 and above.
Evaluating Safety and Immunogenicity
The primary objective of the trial was to assess the safety and immunogenicity of mRNA-1083 alongside two established vaccines. In the age group of 50-64 years, mRNA-1083 was compared to Fluarix, a standard influenza vaccine. Similarly, in the 65-79 age group, mRNA-1083 was evaluated against Fluzone HD, an enhanced influenza vaccine. Furthermore, Moderna also compared mRNA-1083 to their own Spikevax COVID booster for both age cohorts.
Future Plans and Goals
Looking ahead, Moderna anticipates launching the Phase 3 trial in 2023, with the aim of achieving regulatory approval by 2025. The company has already outlined its projections for the future, expecting respiratory product sales to range from $8 billion to $15 billion by 2027. Additionally, this ambitious forecast predicts an operating profit ranging between $4 billion and $9 billion.
Pre-market trading saw the MRNA stock (MRNA, -0.22%) rise by 0.6%. However, it is worth noting that the stock has observed a decline of 43% year-to-date. In contrast, the S&P 500 (SPX) has demonstrated a positive increase of 10%.